Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Morphine sulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The active substance of Actimorph Orodispersible tablets is morphine which belongs to a group of medicines called strong analgesics or 'painkillers' from the opioids group. This medicine has been prescribed by your doctor to relieve severe pain which can be adequately managed only with opioids.
e Actimorph Orodispersible tablets Do not take Actimorph Orodispersible tablets
Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it.
The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to Actimorph if:
If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (See section 3, If you stop taking Actimorph).
Talk to your doctor or pharmacist before taking Actimorph Orodispersible tablets, especially:
Talk to your doctor or pharmacist if you experience any of the following symptoms while taking Actimorph Orodispersible tablets:
Acute generalized exanthematous pustulosis (AGEP) has been reported in association with Actimorph treatment. Symptoms usually occur within the first 10 days of treatment. Tell your doctor if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking Actimorph or other opioids. Stop using Actimorph and seek medical attention immediately, if you notice any of the following symptoms: blistering, widespread scaly skin or pus-filled spots together with fever.
Sleep-related breathing disorders Actimorph Orodispersible tablets can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system. You must only take the tablets by mouth. These tablets should never be dispersed and injected as this may lead to serious side effects, which may be fatal. Elderly people This medicine should be used with caution in the elderly (see section "How to take Actimorph Orodispersible tablets"). Children Do not give this medicine to children under 6 months of age (see section "Do not take Actimorph Orodispersible tablets").
Other medicines and Actimorph Orodispersible tablets Tell your doctor if you are taking, have recently taken or might take any other medicines. This is especially important if you are taking or might take any other medicines mentioned below:
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy This medicine should not be used as much as possible in patients who are pregnant or nursing mothers, unless your doctor deems it absolutely necessary and considers the benefit for you to be significantly greater than the risk for the child. Men and women of child-producing/child bearing potential must use reliable contraception while using Actimorph Orodispersible tablets.
If Actimorph Orodispersible tablets are used for a long time during pregnancy, there is a risk of the new-born child having withdrawal (abstinence) symptoms which should be treated by a doctor. Withdrawal (abstinence) symptoms in babies born to mothers may include high-pitched crying, irritability and restlessness, shaking (tremor), feeding difficulties and sweating. Breast-feeding You should not breast-feed during your treatment with this medicine as morphine is known to pass into breast milk.
Driving and using machines Actimorph Orodispersible tablets may cause a number of side effects such as drowsiness which could affect your ability to drive or use machines (see section 4 for a full list of side effects). These are usually most noticeable when you first start taking this medicine, or when changing to a higher dose. If you are affected, you should not drive or use machinery.
Actimorph Orodispersible tablets contains benzyl alcohol, sodium and sulphites Actimorph 1 mg Orodispersible tablets: This medicine contains 0.1 microgram benzyl alcohol in each orodispersible tablet. Actimorph 2.5 mg Orodispersible tablets: This medicine contains 0.25 microgram benzyl alcohol in each orodispersible. Actimorph 5 mg Orodispersible tablets: This medicine contains 0.5 microgram benzyl alcohol in each orodispersible tablet. Actimorph 10 mg Orodispersible tablets: This medicine contains 0.6 microgram benzyl alcohol in each orodispersible tablet. Actimorph 20 mg Orodispersible tablets: This medicine contains 0.8 microgram benzyl alcohol in each orodispersible tablet. Actimorph 30 mg Orodispersible tablets: This medicine contains 1 microgram benzyl alcohol in each orodispersible tablet. Benzyl alcohol may cause allergic reactions.
Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist.
Ask your doctor or pharmacist for advice if you are pregnant or breast feeding. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis"). Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis").
This medicine contains less than 1 mmol sodium (23 mg) per orodispersible tablet, that is to say essentially 'sodium-free'. Sulphites may rarely cause severe hypersensitivity reactions and bronchospasm. This medicine contains morphine, which is listed as a doping substance. Its use can lead to positive results in anti-doping tests.
Actimorph Orodispersible tablets Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Actimorph, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also, If you stop taking Actimorph, in this section). The dose will depend on the intensity of your pain and your previous history of the need for analgesics. When treating chronic pain, dose according to a fixed shedule should be given preference. Use in adults and adolescents over 16 years The usual starting dose is 10-20 mg every 4-6 hours. Your doctor will decide how many orodispersibles tablets you should take.
If you are still in pain while taking these tablets, talk to your doctor. Do not exceed the dose recommended by your doctor. You should check with your doctor or pharmacist if you are not sure.
Use in elderly patients (over 65 years) A reduction in dose is recommended in the elderly (dose reduction such as 2.5-5 mg every 4-6 hours).
Use in patients with liver or kidney problems This medicine should be administered with particular care in patients with liver or kidney problems. Patients with a suspected delay in the gastrointestinal passage This medicine should be administered with particular care in patients with a suspected delay in the gastrointestinal passage. Use in children and adolescents
Use in adolescents: 13 to 16 years (40-60 kg) The usual starting dose is 5-20 mg every 4-6 hours. Use in children: 6 to 12 years (18-40 kg) The usual starting dose is 5-10 mg every 4-6 hours.
1 to 5 years (9-18 kg) The usual starting dose is 2.5-5 mg every 4-6 hours. over 6 months (6-9 kg) The usual starting dose is 1 mg every 4-6 hours.
Method of administration
Pull off a single dose by tearing along the perforated line on the blister and peel back the foil on the blister to expose the orodispersible tablet. Duration of treatment Do not take this medicine for longer than absolutely necessary. Any change or interruption of treatment should be made as recommended by your doctor (see section "If you stop taking Actimorph Orodispersible tablets").
If you take more Actimorph Orodispersible tablets than you should Call your doctor or hospital straight away as you may need emergency treatment in a hospital. An overdose can have consequences and can be fatal. When seeking medical attention make sure that you take this leaflet and any remaining orodispersible tablets with you to show to the doctor. People who have taken an overdose may have narrow pupils, feel very sleepy, decrease in heart rate, low blood pressure, drop of body temperature, have or get pneumonia from inhaling vomit or foreign matter (symptoms may include breathlessness, cough and fever). People who have taken an overdose may also have breathing difficulties leading to unconsciousness or even death and/or suffer from a brain disorder (known as toxic leukoencephalopathy). In more serious cases, circulatory insufficiency may occur and eventually lead to a deep coma. Muscle damage up to muscle decay can occur (possibly resulting in kidney failure). Under no circumstances should you place yourself in situations that require increased attention, such as driving. The following measures in case of overdose are recommended until a doctor arrives: Keep awake, give breathing commands, breathing aid.
If you forget to take Actimorph Orodispersible tablets If you have taken a lower dose of Actimorph Orodispersible tablets than intended or have completely forgotten to take it, this will result in insufficient or no pain relief. Do not take a double dose to make up for a forgotten dose. Do not take two doses within 4 hours. Continue the use in the recommended manner.
If you stop taking Actimorph Orodispersible tablets Do not stop treatment with Actimorph Orodispersible tablets unless agreed with your doctor. If you want to stop treatment with Actimorph Orodispersible tablets, ask your doctor how to slowly decrease the dose to avoid abstinence (withdrawal) symptoms. Withdrawal symptoms may include body aches, tremors, diarrhea, abdominal pain, nausea, flu-like symptoms, rapid heartbeat and large pupils. Psychological symptoms are a pronounced feeling of dissatisfaction, anxiety and irritability.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop using Actimorph and seek medical attention immediately if you notice any of the following symptoms: Severe skin reaction with blistering, widespread scaly skin, pus-filled spots together with fever. This could be a condition called Acute Generalized Exanthematous Pustulosis (AGEP).
The most serious side effect (uncommon), is a condition where you breathe more slowly or weakly than expected (respiratory depression). Tell your doctor immediately if this happens to you.
This medicine can cause allergic reactions (the frequency of serious allergic reactions is not known). Tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, dizziness, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. The most common side effects of morphine are nausea, vomiting, confusion, constipation and drowsiness.
There is a risk that you may become addicted or reliant on this medicine.
In patients treated with morphine, the following side effects have been reported:
Very common: may affect more than 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Not known: frequency cannot be estimated from the available data
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Actimorph Orodispersible tablets Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month. Store in the original package in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Actimorph Orodispersible tablets contain
What Actimorph Orodispersible tablets look like and contents of the pack Actimorph 1 mg Orodispersible tablets are round, convex, 5 mm of diameter, white tablets engraved "1" on one side and smooth on the other side. Actimorph 2.5 mg Orodispersible tablets are round, convex, 7 mm of diameter, white tablets engraved "2.5" on one side and smooth on the other side. Actimorph 5 mg Orodispersible tablets are round, convex, 8.5 mm of diameter, white tablets engraved "5" on one side and smooth on the other side. Actimorph 10 mg Orodispersible tablets are round, convex, 10 mm of diameter, white tablets engraved "10" on one side and smooth on the other side. Actimorph 20 mg Orodispersible tablets are round, convex, 11 mm of diameter, white tablets engraved "20" on one side and smooth on the other side. Actimorph 30 mg Orodispersible tablets are round, convex, 12 mm of diameter, white tablets engraved "30" on one side and smooth on the other side.
Actimorph Orodispersible tablets are available in packs of 56 orodispersible tablets.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Ethypharm 194, Bureaux de la Colline – Bâtiment D 92213 Saint-Cloud cedex France Manufacturer Ethypharm Chemin de la poudrière 76120 Grand-Quevilly France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: United Kingdom: Ethypharm UK – email: [email protected]. This leaflet was last revised in 03/2025.
C14006 – XXXXX
Actimorph 10 mg Orodispersible tablets comes as tablet containing 10mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Actimorph 10 mg Orodispersible tablets is morphine sulfate.
Medicines with the same active substance, strength and form include: MST Continus 10 mg prolonged release tablets, Morphgesic SR 10mg Tablets, Sevredol tablets 10mg. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Actimorph 10 mg Orodispersible tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Severe pain which can be adequately managed only with opioids.
Treatment goals and discontinuation
Before initiating treatment with Actimorph, a treatment strategy including treatment duration and treatment goals, and a plan for end of treatment, should be agreed together with the patient. In accordance with pain management guidelines, during treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with Actimorph, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
Posology
Actimorph Orodispersible tablets should be administered as follows:
Population
Starting dose
Adults and adolescents over 16 years
10-20 mg of morphine sulfate every 4-6 hours
The dose should then be carefully titrated, every day if necessary, to achieve pain relief.
Patients already receiving opioids may be initiated on higher doses depending on their previous opioid experience.
If used for dose titration Actimorph Orodispersible tablets should be taken in a fixed time schedule (every 4 to 6 hours).
The correct dose for any individual patient is that which will maintain adequate analgesia with acceptable undesirable effects.
The dose can be increased under medical supervision according to the intensity of the pain the sensitivity and the previous history of analgesic requirements of the individual patient.
Duration of treatment
This medicinal product should not be used longer than necessary.
If the need for long-term pain treatment is anticipated in view of the nature and severity of the illness, the patient should be switched to prolonged-release analgesics. The total daily dose should be the same.
If used as breakthrough pain medication, the need for more than two occasions per day is usually an indication that the prolonged-release dose requires upward titration.
Actimorph Orodispersible tablets can be taken with or without food.
Correspondence between the different routes of administration
The posology of morphine varies depending on the route of administration.
Switching from a morphine pharmaceutical form to another must take conversion factors into account in order to maintain the same amount of morphine available.
The dose should be divided by 3 when patients are transferred from an oral morphine form to an intravenous form, and halved when transferred to a subcutaneous form.
Special populations
Elderly
A reduction in dose may be advisable in the elderly (dose reduction such as 2.5-5 mg every 4-6 hours).
Patients with hepatic or renal impairment
In patients with hepatic or renal impairment, Actimorph Orodispersible tablets should be administered with particular care.
Patients with suspected delayed gastrointestinal passage
In patients with suspected delayed gastrointestinal passage, Actimorph Orodispersible tablets should be administered with particular care.
Paediatric population
Population
Starting dose
Adolescents 13-16 years (40-60 kg)
5-20 mg of morphine sulfate (corresponding to about 0.1 to 0.5 mg/kg) every 4-6 hours
Children 6-12 years (18-40 kg)
5-10 mg of morphine sulfate (corresponding to about 0.1 to 0.5 mg/kg) every 4-6 hours
Children 1-5 years (9-18 kg)
2.5-5 mg of morphine sulfate (corresponding to about 0.1 to 0.5 mg/kg) every 4-6 hours
Children > 6 months (6-9 kg)
1 mg of morphine sulfate (corresponding to about 0.1 to 0.2 mg/kg) every 4-6 hours
Actimorph Orodispersible tablets are contraindicated in children under 6 months of age (see section 4.3).
Method of administration
Actimorph Orodispersible tablets are for oral use. The tablet disperses rapidly in the mouth and is then swallowed.
Alternatively, for special population such as children or patients with difficulties in swallowing, the tablet may be placed in a spoon with the addition of a small quantity of water until sufficient dispersion to allow ingestion. This method of administration should be used in children below the age of 6 years.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1,
- Children under 6 months old,
- Severe respiratory depression with hypoxia and/or hypercapnia (in absence of artificial ventilation),
- Severe bronchial asthma,
- Severe chronic obstructive pulmonary disease,
- In acute: cranial trauma and intracranial hypertension in absence of controlled ventilation,
- Uncontrolled epilepsy,
- Acute hepatic disease,
- Acute abdomen,
- Paralytic ileus,
- Delayed gastric emptying,
- Concomitant administration with opioid agonists-antagonists (e.g. buprenorphine, nalbuphine, pentazocine), opioid partial agonists (e.g. naltrexone, nalmefene), sodium oxybate,
- Concurrent administration of mono-amine oxidase inhibitors or within two weeks of discontinuation of their use.
A particularly careful medical supervision and if necessary dose reduction is recommended in the following cases:
- Dependence on opioids, patients with a history of substance abuse,
- Impaired respiratory function,
- Respiratory depression (see below),
- Sleep apnoea,
- Cor pulmonale,
- Head injury, intracranial lesions or conditions with increased intracranial pressure, if ventilation is not performed,
- Impaired consciousness,
- Hypotension with hypovolemia,
- Prostatic hyperplasia with residual urine formation (risk of bladder rupture due to urinary retention),
- Urinary tract narrowing or colic of the urinary tract,
- Biliary tract disorders,
- Obstructive and inflammatory bowel disease,
- Constipation,
- Pheochromocytoma,
- Adrenocortical insufficiency,
- Pancreatitis,
- Severely impaired renal function,
- Severely impaired hepatic function,
- Hypothyroidism,
- Epileptic seizure disorders or increased susceptibility to seizures,
- Elderly patients.
Respiratory depression
The major risk of opioid overdose is respiratory depression.
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Risk from concomitant use of sedative medicinal products such as benzodiazepines or related medicinal products
Concomitant use of Actimorph Orodispersible tablets and sedative medicinal products, such as benzodiazepines or related medicinal products, may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicinal products should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Actimorph Orodispersible tablets concomitantly with sedative medicinal products, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Morphine has an abuse potential similar to other strong agonist opioids and should be used with particular caution in patients with a history of alcohol and drug abuse.
Opioid Use Disorder (abuse and dependence)
Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as Actimorph.
Repeated use of Actimorph can lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment, can increase the risk of developing OUD. Abuse or intentional misuse of Actimorph may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (eg. major depression, anxiety and personality disorders).
Before initiating treatment with Actimorph and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.
Patients will require monitoring for signs of drug-seeking behavior (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Abuse of oral pharmaceutical forms by parenteral administration can be expected to result in serious adverse events, which may be fatal.
Severe cutaneous adverse reactions (SCARs)
Acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, has been reported in association with morphine treatment. Most of these reactions occurred within the first 10 days of treatment. Patients should be informed about the signs and symptoms of AGEP and advised to seek medical care if they experience such symptoms.
If signs and symptoms suggestive of these skin reactions appear, morphine should be withdrawn and an alternative treatment considered.
Acute chest syndrome (ACS) in patients with sickle cell disease (SCD)
Due to a possible association between ACS and morphine use in SCD patients treated with morphine during a vasoocclusive crisis, close monitoring for ACS symptoms is warranted.
Hepatobiliary disorders
Morphine may cause dysfunction and spasm of the sphincter of Oddi, thus raising intrabiliary pressure and increasing the risk of biliary tract symptoms and pancreatitis.
Pre- and postoperative use
Actimorph Orodispersible tablets should be used with caution, pre- and postoperatively, due to the increased risk of ileus or respiratory depression in the postoperative period compared to patients who are not having surgery. Due to the analgesic effect of morphine serious intra-abdominal complications such as bowel perforation can be masked.
Patients who are going to undergo additional procedures to relieve pain (eg plexus block surgery) should not receive Actimorph Orodispersible tablets within 4 hours prior to the intervention. If treatment with Actimorph Orodispersible tablets is indicated, a dose adjustment should be made based on the new post-operative requirements.
Hyperalgesia
Hyperalgesia that does not respond to a further dose increase of morphine may occur in particular in high doses. A morphine dose reduction or change in opioid may be required.
Adrenal insufficiency
Opioid analgesics may cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of adrenal insufficiency may include e.g. nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, or low blood pressure.
Decreased levels of sex hormones and increased prolactin levels
Opioids, such as morphine, may have a pharmacological action on the hypothalamic-pituitary or gonadal axis.
Long-term use of opioid analgesics may be associated with decreased levels of sex hormones and increased prolactin levels. Symptoms include decreased libido, impotence, or amenorrhea.
Concomitant use with rifampicin
Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin.
Oral P2Y12 inhibitor antiplatelet therapy
Within the first day of concomitant P2Y12 inhibitor and morphine treatment, reduced efficacy of P2Y12 inhibitor treatment has been observed (see section 4.5).
Actimorph 10 mg Orodispersible tablets: This medicinal product contains 0.6 microgram benzyl alcohol in each orodispersible tablet.
Benzyl alcohol may cause allergic reactions.
This medicinal product should not be used for more than a week in young children (less than 3 years old).
High quantities should be used with caution and only if necessary, especially in pregnant or breast‑feeding women and in subjects with liver or kidney impairment because of the risk of accumulation and toxicity of benzyl alcohol (metabolic acidosis).
This medicinal product contains sulphites.
May rarely cause severe hypersensitivity reactions and bronchospasm.
This medicinal product contains less than 1 mmol sodium (23 mg) per orodispersible tablet, that is to say essentially 'sodium-free'.
This medicinal product contains morphine, which is listed as a doping substance, and its use can lead to positive results in anti-doping tests.
It must be taken into account that many medicinal products or substances can add their depressant effects of the central nervous system and contribute to decrease vigilance. Medicinal products which depress the CNS include, but are not limited to: other opioids (analgesics, antitussives and substitution treatments), neuroleptics, anxiolytics, sedatives and hypnotics (including benzodiazepines), anxiolytics other than benzodiazepines (eg meprobamate), antiepileptics (including gabapentinoids, e.g., gabapentin or pregabalin), general anaesthetics (including barbiturates), antipsychotics (including phenothiazines), sedative antidepressants (eg amitriptyline, doxepin, mianserine, mirtazapine, trimipramine), sedative H1 antihistamines, muscle relaxants (eg baclofen), thalidomide, central antihypertensives, centrally acting anti-emetics and alcohol. Interactive effects resulting in respiratory depression, hypotension, profound sedation, or coma may result if these drugs are taken in combination with the usual doses of morphine.
Concomitant use contraindicated
+ Morphonic agonists-antagonists (eg buprenorphine, nalbuphine, pentazocine)
Mixed agonist/antagonist opioid analgesics should not be administered to a patient who has received a course of therapy with a pure opioid agonist analgesic as it decreases the analgesic effect by competitive blocking of the receptors, with the risk of appearance of a withdrawal syndrome.
+ Morphic Partial Antagonists (eg Naltrexone, Nalmefene)
Risk of reduction of the analgesic effect.
+ Sodium oxybate
Increased risk of respiratory depression, which can be fatal in case of overdose.
+ Monoamine oxidase inhibitors
MAOIs are known to interact with narcotic analgesics producing CNS excitation or depression with hyper- or hypotensive crisis. Morphine should not be co-administered with monoamine oxidase inhibitors or within two weeks of such therapy.
Concomitant use not recommended
+ Alcohol (drink or excipient)
Alcohol enhancement of the sedative effect of opioid analgesics.
Impaired alertness can make driving dangerous and the use of machinery dangerous.
Since alcohol may enhance the pharmacodynamic effects of Actimorph, concomitant use of alcohol or medicinal products containing alcohol and this medicinal product should be avoided.
+ Sedatives such as benzodiazepines or related medicinal products
The concomitant use of opioids with sedative medicinal products such as benzodiazepines or related medicinal products increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).
Combinations subject to precautions for use
+ Rifampicin
Plasma concentrations and efficacy of morphine and its active metabolite may be reduced by rifampicin (see section 4.4). Clinical surveillance and possible adjustment of morphine dose are advisable during and after discontinuation of rifampicin.
+ Other agonist morphine analgesics (alfentanil, codeine, dextromoramide, dihydrocodeine, fentanyl, hydromorphone, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tapentadol, tramadol)
Increased risk of respiratory depression, which can be fatal in case of overdose.
+ Morphine-like antitussives (eg dextromethorphan, noscapine, pholcodine)
Increased risk of respiratory depression, which can be fatal in case of overdose.
+ True morphine antitussives (eg codeine, ethylmorphine)
Increased risk of respiratory depression, which can be fatal in case of overdose.
+ Barbiturates (eg allobarbital, amobarbital, bartal, butalbital, butobarbital, hexobarbital, methylphenobarbital, phenobarbital, primidone, secbutabarbital, secobarbital, thiopental, vinbarbital, vinylbital)
Increased risk of respiratory depression, which can be fatal in case of overdose.
+ Other sedative medicinal products
Increase of the central depression. Impaired alertness can make driving dangerous and the use of machinery dangerous.
+ Anticholinergic medicinal products
Medicinal products that block the action of acetylcholine, for example atropine, antihistamines, anti-Parkinson's and anti-emetics, may interact with morphine to potentiate the anticholinergic adverse effects. Significant risk of colonic akinesia, with severe constipation.
+ P2Y12 inhibitors
A delayed and decreased exposure to oral P2Y12 inhibitor antiplatelet therapy has been observed in patients with acute coronary syndrome treated with morphine. This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced P2Y12 inhibitor efficacy in patients co-administered morphine and a P2Y12 inhibitor (see section 4.4). In patients with acute coronary syndrome, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.
+ Ritonavir
Although there are no pharmacokinetic data available for concomitant use of ritonavir with morphine, ritonavir induces the hepatic enzymes responsible for the glucuronidation of morphine, and may possibly decrease plasma concentrations of morphine.
+ Cimetidine
Cimetidine inhibits the metabolism of morphine.
Pregnancy
In humans, there are no adequate data available to allow an evaluation of any potential teratogenic risk. There have been reports of a possible link to an increased incident of inguinal hernias. Morphine crosses the placental barrier. Animal studies showed a potential for damage in offspring throughout the entire duration of gestation (see section 5.3). For this reason, morphine must only be used during pregnancy in cases where the maternal benefit clearly outweighs the risk for the child.
Due to the mutagenic properties of morphine, it should not be administered to men and women of child-producing/child bearing potential unless effective contraception is assured.
Newborns whose mothers received opioid analgesics during pregnancy should be monitored for signs of neonatal withdrawal (abstinence) syndrome. Treatment may include an opioid and supportive care.
Parturition
Morphine can prolong or shorten the duration of labour. Neonates, whose mothers are given opioid analgesics during childbirth, should be monitored for signs of respiratory depression or withdrawal syndrome and (if necessary), treated with a specific opioid antagonist.
Breast-feeding
Morphine is excreted into breast milk, where it reaches higher concentrations than in maternal plasma. As clinically relevant concentrations may be reached in nursing infants, breast-feeding is not advised.
Fertility
Animal studies have shown that morphine may reduce fertility (see section 5.3).
Treatment with Actimorph Orodispersible tablets may cause sedation and it is not recommended that patients drive or use machines if they experience drowsiness. This medicinal product can impair cognitive function and can affect the patient's ability to drive safely mainly at treatment initiation, at any change of dose and in case of association with other central nervous system depressants such as alcohol or sedatives.
When the therapy is stabilized, a general driving ban is not mandatory.
In normal doses, the commonest undesirable effects of morphine are nausea, vomiting, confusion, constipation and drowsiness. With chronic therapy, nausea and vomiting are unusual with morphine but should they occur the orodispersible tablets can be readily combined with an anti-emetic if required. Constipation however does not stop while continuing the treatment. All these effects are predictable and need to be treated Constipation may be treated with appropriate laxatives.
The following frequencies are the basis for assessing undesirable effects:
Very common (≥1/10);
Common (≥ 1/100 to < 1/10);
Uncommon (≥ 1/1,000 to < 1/100);
Rare (≥ 1/10,000 to < 1/1,000);
Very rare (< 1/10,000);
Not known (cannot be estimated from the available data).
Systems Organ Classes
Very common
Common
Uncommon
Rare
Very Rare
Not known
Immune system disorders
Hypersensitivity
Anaphylactic reaction
Anaphylactoid reaction
Endocrine disorders
Syndrome of inadequate ADH-secretion (SIADH) (symptom: hyponatremia)
Metabolism and nutrition disorders
Decreased appetite
Psychiatric disorders
Mood altered, mostly Euphoria but also Dysphoria
Confusion
Insomnia
Changes in the activity (mostly decreased activity, but also hyperactivity or agitation)
Thinking disturbances
Cognitive disorders (e.g. hallucinations)
Libido decreased
Drug dependence (see section 4.4)
Nightmare (most often in elderly patients)
Nervous system disorders
Dizziness
Headache
Involuntary muscle contractions
Somnolence
Dysgeusia
Convulsions
Hypertonia
Myoclonus (in case of overdose or too fast dose increase in elderly or patients with kidney failure)
Paraesthesia
Syncope
Tremor
Sedation (dosage dependant)
Intracranial pressure increase, which should be treated at first
Allodynia
Hyperalgesia (see section 4.4)
Light-headedness
Eye disorders
Miosis
Nystagmus
Blurred vision
Double vision (diplopia)
Ear and labyrinth disorders
Vertigo
Cardiac disorders
Palpitations
Bradycardia
Tachycardia
Heart failure
Vascular disorders
Facial flushing
Hypotension
Hypertension
Hot flushes
Respiratory thoracic and mediastinal disorders
Bronchospasm
Pulmonary oedema
Respiratory depression (with apnoea at most)
Dyspnoea
Cough reflex decreased
Non-cardiogenic pulmonary oedema after rapid dose increase
Central sleep apnoea syndrome
Gastrointestinal disorders
Constipation
Nausea
Abdominal pain
Dry mouth
Vomiting (notably at treatment initiation)
Dyspepsia
Paralytic ileus
Pancreatitis (including exacerbation of pancreatitis)
Intestinal obstruction
Dental disease, but a causal relationship to morphine treatment cannot be established.
Hepatobiliary disorders
Biliary colic
Spasm of sphincter of Oddi
Skin and subcutaneous tissue disorders
Rash
Hyperhidrosis
Urticaria
Pruritus
Acute generalised exanthematous pustulosis (AGEP)
Musculoskeletal, connective tissue and bone diseases
Muscle spasms
Muscle rigidity
Renal and urinary disorders
Urinary retention (notably in case of prostatic adenoma or urethral stenosis)
Renal colic
Ureteric spasm
Dysuria
Reproductive system and breast disorders
Amenorrhoea
Erectile dysfunction
General disorders and administration site conditions
Asthenia
Fatigue
Malaise
Peripheral oedema
Shivers
Drug tolerance
Drug withdrawal (abstinence) syndrome
Drug withdrawal (abstinence) syndrome neonatal
Investigations
Hepatic enzymes increased
Description of selected adverse reactions
Drug dependence
Repeated sue of Actimorph can lead to drug dependence, even at therapeutic doses. Téhe risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
Withdrawal (abstinence) syndrome:
An abstinence syndrome may be precipitated when opioid administration is suddenly discontinued or opioid antagonists administered, or can sometimes be experienced between doses. For management, see section 4.4.
Physiological withdrawal symptoms include: body aches, tremors, restless legs syndrome, diarrhoea, abdominal colic, nausea, flu-like symptoms, tachycardia and mydriasis. Psychological symptoms include dysphoric mood, anxiety and irritability. In drug dependence, “drug craving” is often involved.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Toxic doses vary considerably with the individual, a single dose can lead to intoxication whereas regular users may tolerate large doses.
Signs of morphine toxicity and overdose are pin-point pupils (miosis), skeletal muscle flaccidity, bradycardia, hypotension, hypothermia, respiratory depression, pneumonia aspiration, somnolence and central nervous system depression which can progress to stupor or coma. Death may occur from respiratory failure. Circulatory failure and deepening coma may occur in more severe cases. Overdose can result in death. Rhabdomyolysis progressing to renal failure has been reported in opioid overdose.
Toxic leukoencephalopathy has been observed with morphine overdose.
Treatment of morphine overdose
Primary attention should be given to the establishment of a patent airway and institution of assisted or controlled ventilation.
The pure opioid antagonists are specific antidotes against the effects of opioid overdose. Other supportive measures should be employed as needed.
In unconscious patients with respiratory arrest, ventilation, intubation and intravenous administration of an opioid antagonist (eg 0.4-2 mg Naloxone i.v.) are indicated.
If respiratory failure persists, the single dose must be repeated 1 to 3 times at three-minute intervals until the respiratory rate is normalized and the patient responds to painful stimuli.
Strict monitoring (at least 24 hours) is necessary because the effect of the opioid antagonist is shorter than that of morphine, so that respiratory insufficiency can be expected to recur.
The dose of the opioid antagonist in children is 0.01 mg per kg body weight per single dose.
Measures to protect against heat loss and for volume therapy may also be required.
Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to morphine overdose. Naloxone should be administered cautiously to persons who are known, or suspected, to be physically dependent on morphine. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome.
Oral activated charcoal (50 g) for adults, 1 g/kg for children) may be considered if a substantial amount has been ingested within one hour, provided the airway can be protected.
Ask anything about Actimorph 10 mg Orodispersible tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.